Incannex Healthcare Inc. (IXHL)

NCM – Real Time Price. Currency in USD

3.90

-0.63 (-13.91%)

At close: May 12, 2026, 4:00 PM EDT

4.00

+0.10 (2.56%)

Pre-market: May 13, 2026, 7:27 AM EDT

12.05.2026

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced it has been named the winner of the “Best New Technology Solution for Drug Development” award in the 10th annual MedTech Breakthrough Awards program. The award recognizes Incannex's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for the treatment of obstructive sleep apnea (OSA), and reinforces the Company's growing position at the forefront of next-generation therapeutic innovation.

07.05.2026

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide

22.04.2026

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.

27.03.2026

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days

25.03.2026

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation's Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026.

18.03.2026

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors. At current trading levels, Incannex's market capitalization is approximately $46 million — representing a significant disconnect to the Company's $75 million cash position and resulting in a negative enterprise value.

17.03.2026

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

07.05.2026

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

22.04.2026

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

27.03.2026

Incannex Healthcare Inc. (IXHL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videos

No Data

Press releases

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videos

No Data

Press releases

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Search stocks

Incannex Healthcare Inc. (IXHL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videos

No Data

Press releases

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Videos

No Data

Press releases

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position